We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Amphastar Pharmaceuticals (AMPH - Free Report) closed at $45.74, marking a -0.54% move from the previous day. This change lagged the S&P 500's 0.01% gain on the day. Elsewhere, the Dow lost 0.22%, while the tech-heavy Nasdaq added 0.67%.
Heading into today, shares of the specialty pharmaceutical company had lost 15.66% over the past month, lagging the Medical sector's loss of 4.56% and the S&P 500's loss of 4.45% in that time.
Investors will be hoping for strength from Amphastar Pharmaceuticals as it approaches its next earnings release. On that day, Amphastar Pharmaceuticals is projected to report earnings of $0.70 per share, which would represent year-over-year growth of 84.21%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $170.65 million, up 42.05% from the year-ago period.
AMPH's full-year Zacks Consensus Estimates are calling for earnings of $2.72 per share and revenue of $642.66 million. These results would represent year-over-year changes of +38.07% and +28.79%, respectively.
Any recent changes to analyst estimates for Amphastar Pharmaceuticals should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Amphastar Pharmaceuticals is currently a Zacks Rank #3 (Hold).
Looking at its valuation, Amphastar Pharmaceuticals is holding a Forward P/E ratio of 16.89. For comparison, its industry has an average Forward P/E of 15.88, which means Amphastar Pharmaceuticals is trading at a premium to the group.
The Medical - Generic Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 101, putting it in the top 41% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow AMPH in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Amphastar Pharmaceuticals (AMPH - Free Report) closed at $45.74, marking a -0.54% move from the previous day. This change lagged the S&P 500's 0.01% gain on the day. Elsewhere, the Dow lost 0.22%, while the tech-heavy Nasdaq added 0.67%.
Heading into today, shares of the specialty pharmaceutical company had lost 15.66% over the past month, lagging the Medical sector's loss of 4.56% and the S&P 500's loss of 4.45% in that time.
Investors will be hoping for strength from Amphastar Pharmaceuticals as it approaches its next earnings release. On that day, Amphastar Pharmaceuticals is projected to report earnings of $0.70 per share, which would represent year-over-year growth of 84.21%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $170.65 million, up 42.05% from the year-ago period.
AMPH's full-year Zacks Consensus Estimates are calling for earnings of $2.72 per share and revenue of $642.66 million. These results would represent year-over-year changes of +38.07% and +28.79%, respectively.
Any recent changes to analyst estimates for Amphastar Pharmaceuticals should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Amphastar Pharmaceuticals is currently a Zacks Rank #3 (Hold).
Looking at its valuation, Amphastar Pharmaceuticals is holding a Forward P/E ratio of 16.89. For comparison, its industry has an average Forward P/E of 15.88, which means Amphastar Pharmaceuticals is trading at a premium to the group.
The Medical - Generic Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 101, putting it in the top 41% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow AMPH in the coming trading sessions, be sure to utilize Zacks.com.